Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05091723 · ClinicalTrials.gov registry record · Phase 1
TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation
A Phase 1 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05091723: Completed Phase 1 study, sponsored by Theravance Biopharma.
NCT05091723 is a Phase 1 study that has completed, run by Theravance Biopharma. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05091723, a Phase 1 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903) with supplemental oxygenation.
Primary Outcome
The area under the concentration time curve from time 0 extrapolated to infinity (AUC0-inf) of TD-0903
Interventions
- DRUG Nezulcitinib (TD-0903) Dose A
- DRUG Nezulcitinib (TD-0903) Dose B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-10-13 |
| Est. Completion | 2021-11-24 |
| Phase | Phase 1 |
What the finished NCT05091723 record still lists
NCT05091723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Nezulcitinib (TD-0903) Dose A is the first listed.
NCT05091723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05091723 about?
NCT05091723 is a clinical study titled "TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation". This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903) with supplemental oxygenation.
What is the current status of trial NCT05091723?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-10-13. Estimated completion is 2021-11-24.
What interventions are being tested in trial NCT05091723?
The interventions under investigation include: Nezulcitinib (TD-0903) Dose A (DRUG), Nezulcitinib (TD-0903) Dose B (DRUG).
Who is sponsoring clinical trial NCT05091723?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05091723's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy